Travere Therapeutics’ $475 million raise puts spotlight on rare disease execution risk
Rare disease pipelines need time and cash. Travere’s $475 million debt deal shows how biotech balance sheets are being rebuilt.
Rare disease pipelines need time and cash. Travere’s $475 million debt deal shows how biotech balance sheets are being rebuilt.